Drug Store News

Lupin receives FDA nod for generic Risperdal Consta

Lupin has received approval from the Food and Drug Administration for risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial and 50 mg per vial, single-dose vials.
Business Wire

UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy ...
Nasdaq

Teva Pharmaceuticals Reports Positive Real-World Outcomes for UZEDY® (risperidone) in Schizophrenia Treatment Compared to Second-Generation Oral Antipsychotics

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...
Monthly Prescribing Reference

Preventing Relapse in Schizophrenia: Oral vs. Long-Acting Injectable Therapies

A recent report by Buckley et al analyzed a previous study to determine the differences in second and third relapse rates in patients receiving long-acting injectable risperidone versus an oral second ...
Nasdaq

New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)

Switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provided the most comparable pharmacokinetic (PK) profile based on the relevant PK modeling data Additional ...
Medscape

Long-Acting Risperidone Injection

Long-acting risperidone injection was released for marketing for the treatment of schizophrenia in the United States in October 2003. The drug was available in 45 countries as of December 2003. Steady ...
FiercePharma

New Data on INVEGA(R) SUSTENNA(R) and RISPERDAL(R) CONSTA(R) for Schizophrenia to be Presented at Major Psychiatry Meeting

TITUSVILLE, N.J., May 24 /PRNewswire/ --New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone ...
Monthly Prescribing Reference

Additional injection site approved for Risperdal Consta

The FDA has approved the injection of Risperdal Consta (risperidone long-acting injection, from Janssen) into the deltoid muscle of the arm for the treatment of schizophrenia. This approval was based ...
Business Wire

Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia

TEL AVIV, Israel & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals Industries Ltd. (NYSE and TASE: TEVA) and MedinCell (Euronext: MEDCL) today announced positive results for study TV46000-CNS-30072 (the ...
Healio

FDA accepts NDA for subcutaneous risperidone injectable

Please provide your email address to receive an email when new articles are posted on . Teva Pharmaceuticals and MedinCell announced FDA acceptance of a new drug application for risperidone ...
Medscape

Long-Acting Risperidone Injection

Long-acting risperidone is a suspension administered by intramuscular injection in the upper-outer gluteal area. It consists of risperidone impregnated in microspheres composed of a biodegradable, ...